ESMO 2024 | TACTI-003: eftilagimod alpha and pembrolizumab in recurrent/metastatic HNSCC
Claus Andrup Kristensen, MD, PhD, Rigshospitalet, Copenhagen, Denmark, discusses primary results from the Phase IIb TACTI-003 trial (NCT04811027) of eftilagimod alpha plus pembrolizumab versus pembrolizumab alone in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with CPS ≥1. Findings indicate addition of eftilagimod alpha showed numerically higher objective response and disease control rates, especially in patients with CPS ≥20, while maintaining a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
